Literature DB >> 10718151

Proton magnetic resonance spectroscopy of the human brain in schizophrenia.

R F Deicken1, C Johnson, M Pegues.   

Abstract

In vivo proton magnetic resonance spectroscopy (1H MRS) has been utilized by neuroimaging laboratories in recent years to reliably measure compounds such as N-acetylaspartate (NAA), choline (Cho), creatine (Cr), and to a lesser extent glutamate and glutamine in the human brain. To date, the most consistently replicated findings in schizophrenia are reduced NAA measures in the hippocampal regions. Since NAA is thought to be a neuronal/axonal marker and a measure of neuronal/axonal integrity, hippocampal NAA reductions have been interpreted as strong evidence for neuronal/axonal loss or dysfunction in this brain region. The evidence for neuronal loss or dysfunction based on NAA is less consistent for the frontal cortex and white matter, temporal cortex, basal ganglia, cingulate region, and thalamus in schizophrenia. Furthermore, there are no consistently replicated findings for choline or creatine alterations in any of the brain regions examined in schizophrenia. Finally, significant technical difficulties make reliable measurement of glutamine and glutamate problematic at the present time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718151     DOI: 10.1515/revneuro.2000.11.2-3.147

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  11 in total

1.  Metabolic profiling reveals biochemical pathways and potential biomarkers associated with the pathogenesis of Krabbe disease.

Authors:  Nadav I Weinstock; Lawrence Wrabetz; M Laura Feltri; Daesung Shin
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 2.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

Review 3.  Genetically mediated brain abnormalities in schizophrenia.

Authors:  Larry J Seidman; Heidi E Wencel
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 4.  Mitochondrial dysfunction in schizophrenia: an evolutionary perspective.

Authors:  Vanessa F Gonçalves; Ana C Andreazza; James L Kennedy
Journal:  Hum Genet       Date:  2014-10-14       Impact factor: 4.132

5.  Proton magnetic resonance spectroscopy (H-MRS) in chronic schizophrenia. A single-voxel study in three regions involved in a pathogenetic theory.

Authors:  F Granata; G Pandolfo; S Vinci; C Alafaci; N Settineri; R Morabito; A Pitrone; M Longo
Journal:  Neuroradiol J       Date:  2013-07-16

6.  The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia.

Authors:  Dorit Ben-Shachar
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 7.  Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia.

Authors:  Fulvio A Scorza; Andrea Schmitt; Roberta M Cysneiros; Ricardo M Arida; Esper A Cavalheiro; Wagner F Gattaz
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

8.  N-Acetyl-Aspartate Level is Decreased in the Prefrontal Cortex in Subjects At-Risk for Schizophrenia.

Authors:  Marine Mondino; Jerome Brunelin; Mohamed Saoud
Journal:  Front Psychiatry       Date:  2013-09-05       Impact factor: 4.157

9.  N-acetyl aspartate concentration in the anterior cingulate cortex in patients with schizophrenia: a study of clinical and neuropsychological correlates and preliminary exploration of cognitive behaviour therapy effects.

Authors:  Preethi Premkumar; Vivek A Parbhakar; Dominic Fannon; David Lythgoe; Steven C Williams; Elizabeth Kuipers; Veena Kumari
Journal:  Psychiatry Res       Date:  2010-05-21       Impact factor: 3.222

10.  Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression.

Authors:  Dorit Ben-Shachar; Rachel Karry
Journal:  PLoS One       Date:  2008-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.